Dixon Mitchell Investment Counsel’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-16
| Closed | -$1.7K | – | 138 |
|
|
2024
Q2 | $1.7K | Buy |
+16
| New | +$1.61K | ﹤0.01% | 147 |
|
|
2021
Q3 | – | Sell |
-103,207
| Closed | -$9.42M | – | 59 |
|
|
2021
Q2 | $9.42M | Sell |
103,207
-107
| -0.1% | -$9.53K | 0.7% | 40 |
|
|
2021
Q1 | $8.83M | Buy |
103,314
+12,288
| +13% | +$1.1M | 0.73% | 41 |
|
|
2020
Q4 | $8.6M | Sell |
91,026
-132
| -0.1% | -$11.5K | 0.74% | 37 |
|
|
2020
Q3 | $7.93M | Buy |
91,158
+41,200
| +82% | +$3.57M | 0.78% | 37 |
|
|
2020
Q2 | $4.36M | Buy |
49,958
+2,510
| +5% | +$217K | 0.48% | 42 |
|
|
2020
Q1 | $3.91M | Sell |
47,448
-4,113
| -8% | -$367K | 0.49% | 43 |
|
|
2019
Q4 | $4.88M | Buy |
51,561
+1,057
| +2% | +$94.8K | 0.52% | 44 |
|
|
2019
Q3 | $4.39M | Sell |
50,504
-365
| -0.7% | -$32.8K | 0.5% | 46 |
|
|
2019
Q2 | $4.64M | Sell |
50,869
-4,549
| -8% | -$385K | 0.53% | 47 |
|
|
2019
Q1 | $4.77M | Sell |
55,418
-56,880
| -51% | -$4.57M | 0.56% | 47 |
|
|
2018
Q4 | $8.63M | Sell |
112,298
-1,519
| -1% | -$118K | 1.16% | 27 |
|
|
2018
Q3 | $8.79M | Buy |
113,817
+832
| +0.7% | +$61.5K | 1.02% | 29 |
|
|
2018
Q2 | $7.65M | Buy |
112,985
+1,651
| +1% | +$114K | 0.97% | 31 |
|
|
2018
Q1 | $8.07M | Buy |
111,334
+4,142
| +4% | +$315K | 1.07% | 29 |
|
|
2017
Q4 | $8.06M | Buy |
107,192
+7,499
| +8% | +$566K | 1.03% | 33 |
|
|
2017
Q3 | $7.67M | Sell |
99,693
-618
| -0.6% | -$46.7K | 1.02% | 32 |
|
|
2017
Q2 | $7.5M | Buy |
100,311
+1,412
| +1% | +$100K | 1.06% | 32 |
|
|
2017
Q1 | $6.58M | Buy |
98,899
+17,021
| +21% | +$1.13M | 0.95% | 32 |
|
|
2016
Q4 | $5.34M | Buy |
81,878
+4,219
| +5% | +$274K | 0.81% | 38 |
|
|
2016
Q3 | $5.49M | Buy |
77,659
+5,273
| +7% | +$384K | 0.85% | 35 |
|
|
2016
Q2 | $5.35M | Buy |
72,386
+2,586
| +4% | +$179K | 0.89% | 34 |
|
|
2016
Q1 | $4.53M | Buy |
69,800
+949
| +1% | +$64.6K | 0.73% | 41 |
|
|
2015
Q4 | $5.31M | Buy |
68,851
+3,680
| +6% | +$292K | 0.9% | 34 |
|
|
2015
Q3 | $5.37M | Buy |
65,171
+1,485
| +2% | +$132K | 0.93% | 34 |
|
|
2015
Q2 | $5.61M | Buy |
63,686
+1,024
| +2% | +$93.9K | 0.87% | 34 |
|
|
2015
Q1 | $5.54M | Buy |
62,662
+23,369
| +59% | +$2.07M | 0.85% | 33 |
|
|
2014
Q4 | $3.31M | Hold |
39,293
| – | – | 0.51% | 43 |
|
|
2014
Q3 | $3.31M | Buy |
39,293
+839
| +2% | +$67.9K | 0.5% | 44 |
|
|
2014
Q2 | $3.12M | Buy |
38,454
+1,494
| +4% | +$118K | 0.45% | 49 |
|
|
2014
Q1 | $2.82M | Buy |
36,960
+3,332
| +10% | +$243K | 0.44% | 49 |
|
|
2013
Q4 | $2.42M | Buy |
33,628
+2,054
| +7% | +$143K | 0.38% | 50 |
|
|
2013
Q3 | $2.17M | Buy |
31,574
+6,451
| +26% | +$427K | 0.37% | 50 |
|
|
2013
Q2 | $1.59M | Buy |
+25,123
| New | +$1.63M | 0.3% | 52 |
|
Other funds holding NVS
Dixon Mitchell Investment Counsel's NVS Position: Q3 2024 in Review
Dixon Mitchell Investment Counsel sold out of Novartis (NVS) in Q3 2024, closing a stake of 16 shares — an estimated $1.7K sold.
Dixon Mitchell Investment Counsel first reported a position in NVS in Q2 2013 and held it in 34 quarters. The position peaked at $9.42M in Q2 2021. 1,312 funds tracked by Wall St. Rank hold NVS as of Q3 2024.
- Dixon Mitchell Investment Counsel reported no remaining Novartis position as of Q3 2024 after selling out during the quarter.
- Dixon Mitchell Investment Counsel sold 16 Novartis shares in Q3 2024, an estimated $1.7K.
- Dixon Mitchell Investment Counsel first reported a position in Novartis in Q2 2013 and held it in 34 quarters.
- Dixon Mitchell Investment Counsel's Novartis position peaked at $9.42M in Q2 2021.
- 1,312 funds tracked by Wall St. Rank held Novartis as of Q3 2024.
Based on Dixon Mitchell Investment Counsel's 13F filing for Q3 2024, filed 17 Oct 2024.